Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Stimulant or [[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]]

Use the filters below to narrow your results.

generic:
brand:
None (42) · Benzedrex (1) · Cardura, Cardura XL (1) · Hytrin (US brand discontinued); mostly generic (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · Adenosine receptor antagonist (1) · Adenosine receptor antagonist; dopaminergic (1) · Adenosine receptor antagonist; phosphodiesterase inhibitor (1) · Alpha-adrenergic agonist; monoamine releaser (1) · Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1) · AMPA modulator; catecholaminergic (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Dopamine and serotonin reuptake inhibitor; actoprotector (1) · Dopamine reuptake inhibitor; tropane analogue (1) · Dopamine/norepinephrine reuptake inhibitor (5) · Indirect sympathomimetic; norepinephrine releaser (1) · Monoamine releasing agent (8) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Monoamine releasing agent; active ingredient in khat (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Monoamine reuptake inhibitor; sodium channel blocker (1) · N-methyl analogue of 2-AI (1) · Nicotinic acetylcholine receptor agonist (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine releaser (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Norepinephrine–dopamine reuptake inhibitor (2) · Potent dopamine and norepinephrine reuptake inhibitor (1) · Potent dopamine/norepinephrine reuptake inhibitor (1) · Selective norepinephrine reuptake inhibitor (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Trace amine-associated receptor 1 (TAAR1) agonist; monoamine releaser (1) · '"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
uses:
None (43) · '"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) · '"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
starting dose:
None (43) · 1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) · IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1)
preparations:
None (43) · 1, 2, 4, 8 mg IR tablets; 4, 8 mg XL tablets (1) · 1, 2, 5, 10 mg capsules and tablets (1)
fda max:
None (43) · 16 mg/d (IR); 8 mg/d (XL) (1) · 20 mg/d (1)
routes:
None (43) · Oral (2)
onset:
None (43) · BP and symptomatic LUTS improvement within 1-2 weeks (2)
duration:
None (43) · 24 hours (2)
halflife:
None (43) · ~12 hours'"`UNIQ--ref-0000111F-QINU`"' (1) · ~22 hours'"`UNIQ--ref-00000AB0-QINU`"' (1)
bioavailability:
None (43) · >90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) · ~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1)
pregnancy:
None (43) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (43) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 45 results in range #1 to #45.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"